BofA Securities Starts Checkmate Pharmaceuticals (CMPI) at Neutral
Tweet
Share
E-mailGet Alerts CMPI Hot Sheet
Price: $10.50 --0%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Join SI Premium – FREE
BofA Securities initiates coverage on Checkmate Pharmaceuticals (NASDAQ: CMPI) with a Neutral rating and a price target of $19.00.
For an analyst ratings summary and ratings history on Checkmate Pharmaceuticals click here. For more ratings news on Checkmate Pharmaceuticals click here.
Shares of Checkmate Pharmaceuticals closed at $15.58 yesterday.
You May Also Be Interested In
- Wedbush Starts Immunic Inc. (IMUX) at Outperform
- Truist Securities Reinstates Pacira Pharmaceuticals (PCRX) at Buy
- H.C. Wainwright Assumes Alpha Compute Corp. (ALP) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
